$1000 Invested In Edwards Lifesciences 20 Years Ago Would Be Worth This Much Today
Edwards Lifesciences (NYSE: EW) has significantly outperformed the market over the last 20 years, yielding an average annual return of 18.23%. An initial investment of $1000 in EW stock two decades ago would now be valued at $28,476.97, demonstrating the substantial impact of compounded returns over time. The company currently holds a market capitalization of $61.61 billion.
Wall Street Zen Upgrades Zimmer Biomet (NYSE:ZBH) to "Buy"
Wall Street Zen has upgraded Zimmer Biomet (NYSE:ZBH) from a "hold" to a "buy" rating. Despite this upgrade, the broader analyst consensus for ZBH remains "hold" with an average price target of $112.74. The company recently exceeded quarterly earnings and revenue estimates, though insider sales have also been reported.
Edwards Lifesciences Corporation (EW) stock price, news, quote and history
Edwards Lifesciences Corporation (EW) stock is currently trading at $107.15, up 1.28%, with an after-hours price of $106.50. The company, a medical device provider specializing in cardiovascular diseases, has seen a YTD return of 25.69% and a 1-year return of 24.43%. Analysts have an average price target of $113.39, with TD Cowen recently raising its price target to $121 and maintaining a Buy rating.
Edwards Lifesciences (EW) controller has 101 shares withheld for taxes tied to vesting.
Andrew M. Dahl, SVP, Corporate Controller at Edwards Lifesciences (EW), had 101 shares withheld on November 13, 2026, to cover tax obligations related to the vesting of securities. The transaction was valued at $105.80 per share, leaving Dahl with a direct holding of 14,606 shares. This insider trade is a routine tax-related event and is considered to have a neutral impact and sentiment.
Form 4 Edwards Lifesciences Corp: Andrew M. Dahl (SVP, Corporate Controller) For: 13 November
This article reports on a Form 4 filing for Edwards Lifesciences Corp, detailing an insider transaction by Andrew M. Dahl, who serves as SVP and Corporate Controller. The transaction pertains to activities on November 13. The filing is an official disclosure of changes in company ownership by an insider.
Teleflex stock hits 52-week high at 156.75 USD
Teleflex Inc (NYSE:TFX) has reached a new 52-week high of $156.75, reflecting a 29% year-to-date return and a 42.85% increase over the past year. InvestingPro analysis indicates the stock is still undervalued with a Fair Value of $186.80. This performance follows stronger-than-expected Q3 2026 results and analyst price target increases.
Edwards Lifesciences stock hits 52-week high at 105.39 USD By Investing.com
Edwards Lifesciences (EW) stock recently hit a 52-week high of $105.39, driven by a 23% increase over the past year and nearly 35% in the last six months. The medical technology company's strong third-quarter performance, with revenue of $1.716 billion and adjusted EPS of $0.80, exceeded analyst estimates. Despite an InvestingPro analysis suggesting the stock is overvalued with a P/E ratio of 61, several analyst firms have raised their price targets, indicating a positive outlook.
Edwards Lifesciences stock hits 52-week high at 105.39 USD
Edwards Lifesciences (EW) stock reached a new 52-week high of $105.39, reflecting a 23% increase over the past year and nearly 35% in the last six months. This surge is attributed to strong financial results and positive market sentiment, with the company reporting robust third-quarter revenue of $1.716 billion and adjusted EPS of $0.80, exceeding analyst expectations. Despite its performance, InvestingPro analysis indicates the stock may be overvalued relative to its Fair Value.
Form 144 Edwards Lifesciences Corp For: 11 November By Investing.com
This article announces that Edwards Lifesciences Corp. has filed a Form 144 on November 11. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider trading activity. The brief article, published by Investing.com, provides no further details beyond the filing announcement.
Form 144 Edwards Lifesciences Corp For: 11 November By Investing.com
This article from Investing.com announces the filing of Form 144 for Edwards Lifesciences Corp on November 11. It's a concise financial news update, indicating an insider trading disclosure without providing further details about the transaction. The article also lists current market data for various indices, commodities, and shares.
Form 4 Edwards Lifesciences Corp: Daniel J. Lippis (CVP, TAVR) For: 10 November
This article reports on a Form 4 filing for Edwards Lifesciences Corp, specifically detailing a transaction by Daniel J. Lippis, CVP, TAVR, for November 10. Form 4 filings are regulatory documents that disclose changes in the ownership of securities by a company's officers, directors, and any beneficial owner of more than 10% of a class of the company's equity securities. The article provides this information as a direct news update.
Edwards Lifesciences CVP sells $64,530 in shares
Daniel J. Lippis, Corporate Vice President at Edwards Lifesciences Corp, sold 619 common shares for a total of $64,530 after exercising employee stock options. The sale was executed under a Rule 10b5-1 trading plan and occurred while the stock was trading near its 52-week high, with InvestingPro analysis suggesting it is overvalued despite a 35% return in the past six months. Following the transactions, Mr. Lippis directly holds over 40,000 shares of the company.
Anteris Technologies Announces Results for the Third Quarter of 2026
Anteris Technologies reported financial results for Q3 2026, highlighting continued progress in the PARADIGM Trial with expanding enrollment and regulatory clearances in Germany and Australia. The company also announced the occupancy of a new facility in Minnesota to scale production of its DurAVR THVs and ComASUR Delivery System, and appointed Brent Moen as CFO to support commercialization efforts. Net operating cash outflows for the quarter were $22.9 million, primarily due to clinical, regulatory, and manufacturing requirements for the PARADIGM Trial.
Autonomix Medical receives new U.S. patent for catheter sensing technology
Autonomix Medical announced the issuance of a new U.S. Patent for "Medical Devices With Circuitry For Capturing And Processing Physiological Signals." This patent strengthens the intellectual property for their catheter sensing technology, which is designed for high-resolution sensing and real-time physiological monitoring near the biological source. The company believes this technology could have applications in various medical procedures, though it is currently investigational and not cleared for marketing.
Edwards Lifesciences (NYSE:EW) VP Donald Bobo Jr Sells 48,900 Shares of Stock
Edwards Lifesciences VP Donald Bobo Jr. sold 48,900 shares of the company's stock for approximately $5.04 million on November 9, 2026, under a pre-arranged Rule 10b5-1 trading plan. This transaction significantly reduced his holdings by 68.2%, leaving him with 22,798 shares. The company recently reported strong quarterly earnings, beating analyst estimates, and the stock traded up 2.5% following the news.
Form 144 Edwards Lifesciences Corp For: 9 November By Investing.com
This article from Investing.com announces the filing of Form 144 for Edwards Lifesciences Corp on November 9, 2026. Form 144 is a notice of the intent to sell restricted stock. The brief piece notes that Edwards Lifesciences' stock (EW) was up 2.52% at the time of publication.
Raised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open Enrollment
Several healthcare companies, including Johnson & Johnson, Vertex Pharmaceuticals, Humana, Edwards Lifesciences, and McKesson, reported positive developments amidst Medicare Open Enrollment. Four of the five companies raised their full-year guidance, and Johnson & Johnson received accelerated FDA approval for a new cancer therapy. These updates highlight significant activity in the pharmaceutical, biotechnology, health insurance, medical devices, and drug distribution sectors.
Edwards Lifesciences stock rating maintained at Buy by TD Cowen
TD Cowen has reiterated a Buy rating and a $117.00 price target for Edwards Lifesciences (NYSE:EW), citing the company's strong position in the transcatheter mitral and tricuspid therapies market. Despite the stock appearing overvalued by some metrics, analysts see significant upside potential, particularly with the growth of its PASCAL and EVOQUE products. Other firms like Truist Securities, Wells Fargo, and Mizuho have also raised their price targets following strong third-quarter results.
Edwards Lifesciences CVP Daveen Chopra sells $2.9M in stock
Daveen Chopra, Corporate Vice President at Edwards Lifesciences Corp (NASDAQ:EW), sold 31,800 shares of company stock for approximately $2.89 million after exercising employee stock options. This insider sale occurred while the stock was trading near its 52-week high, following a recent 9.5% gain. The company recently reported strong Q3 2026 results, surpassing expectations, and several analyst firms subsequently raised their price targets.
Form 4 Edwards Lifesciences Corp: Daveen Chopra (CVP, TMTT, Surgical & IHFM) For: 26 August
This article announces a Form 4 filing for Edwards Lifesciences Corp, specifically detailing a transaction involving Daveen Chopra, who holds the title of CVP, TMTT, Surgical & IHFM. The filing is dated for August 26. The article itself is a brief notification from Investing.com.
What Edwards Lifesciences Stock Beat And Raised Outlook Means For Shareholders
Edwards Lifesciences (NYSE: EW) reported strong third-quarter 2026 sales and net income, leading to raised full-year guidance for sales growth and transcatheter product groups. The company's investment narrative is driven by procedure volumes, particularly TAVR and other transcatheter therapies, with recent clinical trial data and expanded Medicare coverage supporting growth. While the outlook is positive due to increased procedure trends, potential risks include margin pressure from tariffs, legal costs, and one-off items that could affect profitability.
Align Technology, Inc. (ALGN) stock price, news, quote and history
Align Technology, Inc. (ALGN) is a medical instruments and supplies company providing Invisalign clear aligners and iTero intraoral scanners. The article provides a detailed overview of ALGN's stock performance, key financial metrics, earnings trends, and analyst insights. It also includes company details, recent news, and comparative performance against the S&P 500.
Edwards Lifesciences Corporation (EW) stock price, news, quote and history
This article provides a detailed overview of Edwards Lifesciences Corporation (EW), including its stock price, historical data, and key financial metrics. It highlights the company's products for cardiovascular diseases, its market performance compared to the S&P 500, and recent analyst ratings. The information aims to give investors a comprehensive look at EW's current status and future outlook.
Edwards Lifesciences Corporation $EW Stock Sold by Boston Trust Walden Corp
Boston Trust Walden Corp reduced its stake in Edwards Lifesciences Corporation (NYSE:EW) by 5.3% in the third quarter, selling 13,624 shares while retaining a substantial holding valued at over $21 million. This reduction occurred despite other institutional investors, like Assenagon Asset Management S.A., increasing their positions. Edwards Lifesciences reported strong Q3 earnings, beating analyst estimates with EPS of $0.80 and revenue of $1.72 billion, leading to a "Moderate Buy" consensus rating from analysts with an average price target of $108.88.
Edwards Lifesciences (EW) Could Be 21% Undervalued After Earnings Guidance And Trial Data
Edwards Lifesciences (EW) has seen a significant shift in sentiment, with its stock up 16.6% in the last month and 18.2% year-to-date, following positive third-quarter results, increased full-year sales guidance, and fresh clinical trial data. While the stock trades near its average analyst target, one fair value estimate suggests it could be 21% undervalued. However, its current P/E ratio of 58.3x is significantly higher than the industry average, posing a valuation risk for investors focused on earnings multiples.
Cardinal Health Raises FY2027 Guidance Despite 28% Profit Drop In Medical Products Segment
Cardinal Health increased its fiscal 2027 non-GAAP EPS guidance to $12.80–$13, following a rise in first-quarter non-GAAP EPS to $3.26, despite a 28% decline in profit from its medical products division. The company's optimistic outlook is attributed to strong performance in pharmaceutical and specialty solutions, as well as other growth businesses. Additionally, Cardinal Health has renewed contracts representing nearly two-thirds of its enterprise revenue over the past year, including a binding letter of intent to renew its CVS pharmacy agreements through 2032.
Edwards Lifesciences stock rating reiterated at Buy by TD Cowen
TD Cowen has reiterated a Buy rating on Edwards Lifesciences (NYSE: EW) and maintained a $117.00 price target, citing the company's strong third-quarter performance that exceeded revenue and adjusted earnings per share expectations. The firm highlighted robust growth in TAVR and TMTT segments, and views management's fourth-quarter targets as highly achievable, keeping Edwards Lifesciences as its top large-cap pick. Other firms like Truist Securities, Wells Fargo, and Mizuho also raised their price targets following the impressive results.
Laureate unit in Peru buys UCAL for ~$35M to expand Lima capacity
Laureate Education's Peruvian subsidiary, Universidad Peruana de Ciencias Aplicadas (UPC), acquired Universidad de Ciencias y Artes de América Latina (UCAL) for approximately $35 million on November 5, 2026. This acquisition, which includes campus real estate valued at $25 million, will expand UPC's capacity in Metropolitan Lima, adding nearly 2,500 students with room for up to 5,000. The move addresses strong demand and limited growth options for UPC's existing campuses.
Edwards Lifesciences (EW) Stock Looks Fully Priced On Cash Flow
Edwards Lifesciences (EW) has seen a strong 50% share gain over the past three years. However, a Discounted Cash Flow (DCF) analysis suggests the current stock price of US$99 is significantly above its intrinsic value based on projected cash flows, especially considering recent clinical trial data that raises questions about the expansion of the TAVR market. Investors are encouraged to consider the company's "roughly fairly valued" narrative and specific business risks beyond its cash flow profile.
Marea Therapeutics to present at major November investor conferences on new cardioendocrine drug developments
Marea Therapeutics, a subsidiary of Lisata Therapeutics, will present at major investor conferences in November, including the Guggenheim Healthcare Innovation Conference and Jefferies Global Healthcare Conference. The company will provide updates on its lead drug candidates, MAR001 for severe hypertriglyceridemia and MAR002 for acromegaly, both in clinical development. Webcasts of these presentations will be available on Lisata's investor website to inform investors about the progress and future plans for these cardioendocrine disease treatments.
Cartesian Therapeutics reports Q3 2026 results; Phase 3 trial data for Descartes-08 in MG expected Q1 2027.
Cartesian Therapeutics announced its Q3 2026 financial results, reporting a net loss of $11.5 million but with $124.7 million in cash to fund operations into 2028. The company is progressing with its Phase 3 AURORA trial for Descartes-08 in myasthenia gravis, expecting data in Q1 2027 and a biologics license application filing in mid-2027. Additionally, Cartesian is advancing Phase 2 and Phase 1/2 trials for myositis and juvenile dermatomyositis, with data anticipated in the first half of 2027.
Wells Fargo raises Edwards Lifesciences price target on Q3 beat
Wells Fargo increased its price target for Edwards Lifesciences (NYSE:EW) to $113 from $100, maintaining an "Overweight" rating after the company reported strong third-quarter results. The company surpassed revenue and adjusted EPS estimates, leading to an upward revision of its 2026 guidance. Mizuho also raised its price target for Edwards Lifesciences to $120.
Truist Financial Upgrades Edwards Lifesciences (NYSE:EW) to Strong-Buy
Truist Financial has upgraded Edwards Lifesciences (NYSE:EW) from a "hold" to a "strong-buy" rating. This upgrade follows Edwards Lifesciences' strong quarterly earnings, where the company surpassed analyst expectations for both earnings per share and revenue, demonstrating 10.5% year-over-year revenue growth. The company also saw positive clinical trial results for its PASCAL tricuspid repair system and TAVR for moderate aortic stenosis, contributing to a "Moderate Buy" consensus rating and an average price target of $101.88 across analysts.
Wells Fargo raises Edwards Lifesciences price target on Q3 beat By Investing.com
Wells Fargo increased its price target for Edwards Lifesciences (NYSE:EW) to $113 from $100, maintaining an Overweight rating, after the company exceeded third-quarter expectations with sales of $1.716 billion and adjusted EPS of $0.80. Mizuho also raised its price target to $120. The company's strong performance across its cardiovascular segments, particularly transcatheter aortic valve replacement, led to an upward revision of its 2026 guidance, though InvestingPro analysis suggests the stock is currently overvalued.
Mizuho raises Edwards Lifesciences stock price target on TAVR beat
Mizuho has increased its price target for Edwards Lifesciences (NYSE:EW) stock to $120 from $105, maintaining an Outperform rating, following the company's strong third-quarter earnings. The beat was primarily driven by robust performance in transcatheter aortic valve replacement (TAVR) and transcatheter mitral and tricuspid therapies (TMTT), leading Edwards Lifesciences to raise its full-year TAVR guidance. Despite the stock trading near its 52-week high, InvestingPro analysis indicates it may be overvalued relative to its Fair Value.
10,415 Shares of Zimmer Biomet Holdings, Inc. $ZBH Acquired by Associated Banc Corp
Associated Banc Corp recently acquired 10,415 shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), valued at approximately $925,000, as disclosed in its latest 13F filing. Zimmer Biomet reported better-than-expected third-quarter earnings and revenue, leading to a raised 2026 outlook, despite ongoing challenges with weak knee sales and margin pressure. Institutional investors now own 88.89% of the medical equipment provider's stock, with analysts generally maintaining a "Hold" rating.
Edwards Lifesciences Reports Third Quarter Results
Edwards Lifesciences announced strong third-quarter 2026 financial results, with sales growing 10.5% to $1.72 billion and adjusted EPS increasing 19% to $0.80. The company raised its full-year 2026 sales and adjusted EPS guidance, driven by broad-based performance across its Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical businesses. Key achievements include new regulatory approvals for several heart devices and positive clinical trial data presented at TCT 2026.
Edwards Lifesciences Q3 2026 Earnings Call Transcript
Edwards Lifesciences (NYSE: EW) reported strong third-quarter 2026 results, with sales of $1.72 billion, an 11.2% increase, driven by its structural heart portfolio including TAVR and TMTT therapies. The company raised its full-year sales growth guidance to approximately 11.5% and adjusted EPS guidance to $2.97-$3.05. Management highlighted significant progress in clinical, regulatory, and commercial priorities, including multiple therapy approvals and new clinical data, reinforcing confidence in long-term growth.
Edwards Lifesciences earnings beat by $0.06, revenue topped estimates
Edwards Lifesciences (NYSE: EW) reported third-quarter EPS of $0.80, exceeding analyst estimates by $0.06, and revenue of $1.72 billion, surpassing the consensus of $1.68 billion. The company also provided FY 2026 EPS guidance of $2.97-$3.05, aligning with analyst expectations. Edwards Lifesciences' stock has shown significant growth, up 10.76% in the last 3 months and 19.95% in the last 12 months.
Edwards Lifesciences earnings beat by $0.06, revenue topped estimates
Edwards Lifesciences (NYSE: EW) reported strong third-quarter results, beating analyst estimates with an EPS of $0.80, exceeding the $0.74 forecast, and revenue of $1.72 billion, surpassing the $1.68 billion consensus. The company also provided FY 2026 EPS guidance of $2.97-$3.05, aligning with analyst expectations. The stock has seen significant positive performance, up 10.76% in the last 3 months and 19.95% in the last 12 months.
Edwards Lifesciences (EW) Trial Results Put Earlier TAVR Use In Focus
Edwards Lifesciences (NYSE:EW) announced positive results from its PROGRESS Trial, showing clinical benefits for Transcatheter Aortic Valve Replacement (TAVR) in patients with moderate aortic stenosis. The trial demonstrated reductions in heart failure events and hospitalizations, alongside improved quality of life for TAVR recipients. These findings reinforce the potential for broader TAVR use in underpenetrated patient groups and may influence future treatment guidelines.
What Do Edwards Lifesciences (NYSE:EW) Trial Results Reveal?
Edwards Lifesciences presented positive results from two randomized trials at the annual TCT meeting, influencing the debate on valve disease intervention. The PROGRESS trial favored early aortic valve replacement in moderate narrowing patients, reducing deaths and heart failure events. A separate CLASP II TR study demonstrated the PASCAL system's effectiveness for leaky tricuspid valves, improving health status compared to medical therapy alone.
Tenet Healthcare Corporation stock hits all-time high at 285.71 USD
Tenet Healthcare Corporation (THC) stock has reached an all-time high of $285.71, reflecting strong performance and investor confidence. The company reported impressive third-quarter 2026 results, surpassing analyst expectations with adjusted EPS of $6.64 and revenue of $5.63 billion, and raised its full-year adjusted EBITDA outlook. Analysts from Mizuho and Guggenheim have maintained positive ratings and price targets, with InvestingPro analysis suggesting the stock remains undervalued.
Edwards Lifesciences stock hits 52-week high at 98.7 USD
Edwards Lifesciences (EW) stock has reached a new 52-week high of $98.70, reflecting a 13.12% total return over the past year due to strong market demand and innovative products. Despite an InvestingPro analysis suggesting it may be overvalued with a P/E of 57.03, the company maintains "GREAT" financial health and is expected to release positive earnings on November 4th, with analysts from TD Cowen, Truist Securities, and UBS reiterating positive outlooks based on trial results and revenue projections.
Edwards Lifesciences stock hits 52-week high at 98.7 USD By Investing.com
Edwards Lifesciences (EW) stock recently hit a 52-week high of $98.70, reflecting a 13.12% total return over the past year. Despite a P/E ratio of 57.03 and being considered overvalued by InvestingPro, the company posted 14.55% revenue growth and maintains a "GREAT" financial health score. Upcoming earnings are projected to show a 9% year-over-year revenue growth, with positive analyst ratings based on strong market demand and clinical trial results, though some risks are noted.
This Edwards Lifesciences Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Several top Wall Street analysts have upgraded their ratings for five companies. Edwards Lifesciences Corp (NYSE: EW) was upgraded from Hold to Buy with a raised price target of $113, while MSG Knickerbockers Corp (NYSE: MSGK) moved from Peer Perform to Outperform. Other upgrades include Ouster, Inc. (NASDAQ: OUST) from Neutral to Overweight with a $45 price target, Navitas Semiconductor Corporation (NASDAQ: NVTS) from Neutral to Buy, and Archer-Daniels-Midland Company (NYSE: ADM) from Underweight to Neutral.
Edwards Lifesciences Corp. stock outperforms competitors on strong trading day
Edwards Lifesciences Corp. (EW) shares rose 2.07% to $95.19 on Tuesday, marking its second consecutive day of gains. The stock outperformed the broader market, as the S&P 500 Index increased 0.36% while the Dow Jones Industrial Average fell 0.38%.
After a year, 80% had moderate-or-less valve leakage with a repair device, versus 30% on medication.
Edwards Lifesciences announced that its PASCAL system for tricuspid repair showed superior clinical and quality-of-life benefits compared to medical therapy alone in the CLASP II TR trial. At one year, 80% of PASCAL-treated patients had moderate or less tricuspid regurgitation, significantly outperforming the 30% in the control group. The system also demonstrated a clinically significant improvement in patient quality-of-life measures, with low adverse event rates.
Edwards PASCAL system shows superiority in tricuspid repair trial
Edwards Lifesciences announced that its PASCAL system for tricuspid repair demonstrated superiority over medical therapy alone in the CLASP II TR trial, meeting its primary endpoint at six months and sustaining results for one year. The trial showed that 80% of patients treated with the PASCAL system achieved moderate or less tricuspid regurgitation at one year, compared to 30% in the control group, along with significant improvements in quality of life and low adverse event rates. The PASCAL system received FDA approval in October 2026 and CE Mark in 2020, and has been used to treat thousands of patients globally.
A valve procedure cut heart failure hospitalizations by over half versus monitoring in a trial
The PROGRESS Trial by Edwards Lifesciences demonstrated that transcatheter aortic valve replacement (TAVR) is superior to clinical surveillance for moderate aortic stenosis (AS) patients with at-risk features. TAVR led to a 33% reduction in death or heart failure events, and heart failure hospitalizations were cut by over 50%. These findings suggest a paradigm shift towards a more proactive approach in managing moderate AS, challenging the previous assumption of passive surveillance.